UK VC firm launches strategic review, ponders shutdown
13 Jul 2023
Acquisition
Arix Bioscience is conducting a strategic review that could include winding down the UK-based venture capital firm.
Arix said it is evaluating its investment strategies and its policies around allocating capital and returns to shareholders, and it is also considering “a tax-efficient wind-down of the company,” the VC’s board announced Thursday in a securities
filing
.
The firm touts a dozen biotech companies in its portfolio, including Takeda-backed Ensoma, Evommune, Aura Biosciences and Disc Medicine, which went
public
last year via a reverse merger with Gemini Therapeutics. Evommune
announced
in April it raised $50 million in a Series B, with Arix co-leading the round.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.